Haploidentical transplantation outcomes for secondary acute myeloid leukemia::  ALWP of the EBMT study

Zhuoyan Li; Myriam Labopin; Fabio Ciceri; Didier Blaise; Johanna Tischer; Gerhard Ehninger; M. T. Van Lint; Yener Koc; Stella Santarone; Edouard Forcade; Luca Castagna; Emmanuelle Polge; Audrey Mailhol; Annalisa Ruggeri; Mohamad Mohty; Bipin N. Savani; Arnon Nagler

doi:10.1002/ajh.25087

Haploidentical transplantation outcomes for secondary acute myeloid leukemia: ALWP of the EBMT study

Zhuoyan Li, Myriam Labopin, Fabio Ciceri, Didier Blaise, Johanna Tischer, Gerhard Ehninger, M. T. Van Lint, Yener Koc, Stella Santarone, Edouard Forcade, Luca Castagna, Emmanuelle Polge, Audrey Mailhol, Annalisa Ruggeri, Mohamad Mohty, Bipin N. Savani, Arnon Nagler

Research output: Contribution to journal › Article

Abstract

Secondary acute myeloid leukemia (sAML) traditionally has inferior outcomes compared to de novo AML. Allogeneic hematopoietic cell transplantation (HCT) is the sole potentially curative therapy. This study analyzes the outcomes for unmanipulated haploidentical HCT (haploHCT) for sAML using the Acute Leukemia Working Party (ALWP) registry of the European Society for Blood and Marrow Transplantation (EBMT). We identified 154 patients with sAML who underwent haploHCT from 2006 to 2016. Median age at HCT was 60 years with time from diagnosis to HCT 5 months. At transplantation, 69 patients were in first CR and 85 had active disease. Fifty-seven (38.0%) patients underwent myeloablative conditioning and 97 (62.0%) reduced intensity conditioning (RIC) conditioning. Multivariate analysis showed that there was no difference in RI, nonrelapse mortality (NRM), leukemia free survival (LFS), overall survival (OS), or GVHD-free/relapse free survival (GRFS) for conditioning intensity, age, performance status, or graft source. Active disease was associated with higher RI and inferior LFS, OS, and GRFS compared with patients in CR at time of transplant. T-cell depletion with anti-thymoglobulin resulted in higher NRM and inferior LFS, OS, and GRFS compared to post-transplant cyclophosphamide (PTCy) (HR 2.25, 2.01, 2.16, and 1.73, respectively with P values

Original language	English
Pages (from-to)	769-777
Number of pages	9
Journal	American Journal of Hematology
Volume	93
Issue number	6
DOIs	https://doi.org/10.1002/ajh.25087
Publication status	Published - Jun 1 2018

Fingerprint

Cite this

Li, Z., Labopin, M., Ciceri, F., Blaise, D., Tischer, J., Ehninger, G., Van Lint, M. T., Koc, Y., Santarone, S., Forcade, E., Castagna, L., Polge, E., Mailhol, A., Ruggeri, A., Mohty, M., Savani, B. N., & Nagler, A. (2018). Haploidentical transplantation outcomes for secondary acute myeloid leukemia: ALWP of the EBMT study. American Journal of Hematology, 93(6), 769-777. https://doi.org/10.1002/ajh.25087

Haploidentical transplantation outcomes for secondary acute myeloid leukemia: ALWP of the EBMT study. / Li, Zhuoyan; Labopin, Myriam; Ciceri, Fabio; Blaise, Didier; Tischer, Johanna; Ehninger, Gerhard; Van Lint, M. T.; Koc, Yener; Santarone, Stella; Forcade, Edouard; Castagna, Luca; Polge, Emmanuelle; Mailhol, Audrey; Ruggeri, Annalisa; Mohty, Mohamad; Savani, Bipin N.; Nagler, Arnon.

In: American Journal of Hematology, Vol. 93, No. 6, 01.06.2018, p. 769-777.

Research output: Contribution to journal › Article

Li, Z, Labopin, M, Ciceri, F, Blaise, D, Tischer, J, Ehninger, G, Van Lint, MT, Koc, Y, Santarone, S, Forcade, E, Castagna, L, Polge, E, Mailhol, A, Ruggeri, A, Mohty, M, Savani, BN & Nagler, A 2018, 'Haploidentical transplantation outcomes for secondary acute myeloid leukemia: ALWP of the EBMT study', American Journal of Hematology, vol. 93, no. 6, pp. 769-777. https://doi.org/10.1002/ajh.25087

Li, Zhuoyan ; Labopin, Myriam ; Ciceri, Fabio ; Blaise, Didier ; Tischer, Johanna ; Ehninger, Gerhard ; Van Lint, M. T. ; Koc, Yener ; Santarone, Stella ; Forcade, Edouard ; Castagna, Luca ; Polge, Emmanuelle ; Mailhol, Audrey ; Ruggeri, Annalisa ; Mohty, Mohamad ; Savani, Bipin N. ; Nagler, Arnon. / Haploidentical transplantation outcomes for secondary acute myeloid leukemia: ALWP of the EBMT study. In: American Journal of Hematology. 2018 ; Vol. 93, No. 6. pp. 769-777.

@article{0ba0d43166214eb08da1cacbb98a8457,

title = "Haploidentical transplantation outcomes for secondary acute myeloid leukemia:: ALWP of the EBMT study",

abstract = "Secondary acute myeloid leukemia (sAML) traditionally has inferior outcomes compared to de novo AML. Allogeneic hematopoietic cell transplantation (HCT) is the sole potentially curative therapy. This study analyzes the outcomes for unmanipulated haploidentical HCT (haploHCT) for sAML using the Acute Leukemia Working Party (ALWP) registry of the European Society for Blood and Marrow Transplantation (EBMT). We identified 154 patients with sAML who underwent haploHCT from 2006 to 2016. Median age at HCT was 60 years with time from diagnosis to HCT 5 months. At transplantation, 69 patients were in first CR and 85 had active disease. Fifty-seven (38.0%) patients underwent myeloablative conditioning and 97 (62.0%) reduced intensity conditioning (RIC) conditioning. Multivariate analysis showed that there was no difference in RI, nonrelapse mortality (NRM), leukemia free survival (LFS), overall survival (OS), or GVHD-free/relapse free survival (GRFS) for conditioning intensity, age, performance status, or graft source. Active disease was associated with higher RI and inferior LFS, OS, and GRFS compared with patients in CR at time of transplant. T-cell depletion with anti-thymoglobulin resulted in higher NRM and inferior LFS, OS, and GRFS compared to post-transplant cyclophosphamide (PTCy) (HR 2.25, 2.01, 2.16, and 1.73, respectively with P values ",

author = "Zhuoyan Li and Myriam Labopin and Fabio Ciceri and Didier Blaise and Johanna Tischer and Gerhard Ehninger and {Van Lint}, {M. T.} and Yener Koc and Stella Santarone and Edouard Forcade and Luca Castagna and Emmanuelle Polge and Audrey Mailhol and Annalisa Ruggeri and Mohamad Mohty and Savani, {Bipin N.} and Arnon Nagler",

year = "2018",

month = jun

day = "1",

doi = "10.1002/ajh.25087",

language = "English",

volume = "93",

pages = "769--777",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "6",

}

TY - JOUR

T1 - Haploidentical transplantation outcomes for secondary acute myeloid leukemia:

T2 - ALWP of the EBMT study

AU - Li, Zhuoyan

AU - Labopin, Myriam

AU - Ciceri, Fabio

AU - Blaise, Didier

AU - Tischer, Johanna

AU - Ehninger, Gerhard

AU - Van Lint, M. T.

AU - Koc, Yener

AU - Santarone, Stella

AU - Forcade, Edouard

AU - Castagna, Luca

AU - Polge, Emmanuelle

AU - Mailhol, Audrey

AU - Ruggeri, Annalisa

AU - Mohty, Mohamad

AU - Savani, Bipin N.

AU - Nagler, Arnon

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Secondary acute myeloid leukemia (sAML) traditionally has inferior outcomes compared to de novo AML. Allogeneic hematopoietic cell transplantation (HCT) is the sole potentially curative therapy. This study analyzes the outcomes for unmanipulated haploidentical HCT (haploHCT) for sAML using the Acute Leukemia Working Party (ALWP) registry of the European Society for Blood and Marrow Transplantation (EBMT). We identified 154 patients with sAML who underwent haploHCT from 2006 to 2016. Median age at HCT was 60 years with time from diagnosis to HCT 5 months. At transplantation, 69 patients were in first CR and 85 had active disease. Fifty-seven (38.0%) patients underwent myeloablative conditioning and 97 (62.0%) reduced intensity conditioning (RIC) conditioning. Multivariate analysis showed that there was no difference in RI, nonrelapse mortality (NRM), leukemia free survival (LFS), overall survival (OS), or GVHD-free/relapse free survival (GRFS) for conditioning intensity, age, performance status, or graft source. Active disease was associated with higher RI and inferior LFS, OS, and GRFS compared with patients in CR at time of transplant. T-cell depletion with anti-thymoglobulin resulted in higher NRM and inferior LFS, OS, and GRFS compared to post-transplant cyclophosphamide (PTCy) (HR 2.25, 2.01, 2.16, and 1.73, respectively with P values

AB - Secondary acute myeloid leukemia (sAML) traditionally has inferior outcomes compared to de novo AML. Allogeneic hematopoietic cell transplantation (HCT) is the sole potentially curative therapy. This study analyzes the outcomes for unmanipulated haploidentical HCT (haploHCT) for sAML using the Acute Leukemia Working Party (ALWP) registry of the European Society for Blood and Marrow Transplantation (EBMT). We identified 154 patients with sAML who underwent haploHCT from 2006 to 2016. Median age at HCT was 60 years with time from diagnosis to HCT 5 months. At transplantation, 69 patients were in first CR and 85 had active disease. Fifty-seven (38.0%) patients underwent myeloablative conditioning and 97 (62.0%) reduced intensity conditioning (RIC) conditioning. Multivariate analysis showed that there was no difference in RI, nonrelapse mortality (NRM), leukemia free survival (LFS), overall survival (OS), or GVHD-free/relapse free survival (GRFS) for conditioning intensity, age, performance status, or graft source. Active disease was associated with higher RI and inferior LFS, OS, and GRFS compared with patients in CR at time of transplant. T-cell depletion with anti-thymoglobulin resulted in higher NRM and inferior LFS, OS, and GRFS compared to post-transplant cyclophosphamide (PTCy) (HR 2.25, 2.01, 2.16, and 1.73, respectively with P values

U2 - 10.1002/ajh.25087

DO - 10.1002/ajh.25087

M3 - Article

VL - 93

SP - 769

EP - 777

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 6

ER -

Access to Document

10.1002/ajh.25087